Despite the perception of many oncologists that tamoxifen is an inferior drug, and should be substituted by an aromatase inhibitor in post-menopausal women, the current evidence strongly supports the view that AIs should be used 2–3 years after tamoxifen to achieve the maximal overall survival (OS) advantage. The last year has been an interesting time for oncologists interested in the adjuvant hormonal treatment of post-menopausal women with receptor-positive early breast cancer. Three important new pieces of clinical research were presented at the 2008 San Antonio Breast Cancer Symposium: a meta-analysis of the Aromatase Inhibitor (AI) trials (Ingle et al, 2008b)...